Viracta Therapeutics entered into a loan and security agreement with Silicon Valley Bank and Oxford Finance for up to $50.0 million. The new credit facility supersedes a prior $15.0 million loan and refinanced an existing $5.0 million debt balance. Under the agreement, $45.0 million remains available in two additional tranches of $20.0 million and $25.0 million. The facility is structured as a loan and security agreement provided by SVB and Oxford Finance. The company is under no obligation to draw on the remaining tranches. No operating metrics or additional financial details were disclosed in the announcement. Viracta Therapeutics, Inc. announced it received approximately $65 million in funding. The company closed the transaction on February 24, 2021. It raised $64,999,994 pursuant to Regulation D from 26 investors. The articles describe the backers only as a group of investors and do not name any participants. The reporting includes no operating metrics, product details, future plans, prior financings, founding year, or location. Beyond this Regulation D raise, the company’s broader financial situation is not disclosed in the articles. Viracta Therapeutics is a San Diego, CA–based precision oncology company targeting virus-associated malignancies. Led by President and CEO Ivor Royston, the company’s proprietary lead molecule, nanatinostat, is being evaluated orally in combination with valganciclovir in a Phase 2 trial for Epstein‑Barr virus–positive lymphomas. Viracta describes this as a Kick and Kill approach and is pursuing its application in other EBV‑associated malignancies such as nasopharyngeal carcinoma and other virus-related cancers. The company closed a Series D financing of an undisclosed amount led by Taiwania Capital Management with participation from existing investors. In conjunction with the financing, Michael Huang, Managing Partner at Taiwania, joined Viracta’s Board of Directors. Proceeds are expected to be used to complete the Phase 2 study, support subsequent initiation of registration studies and for general corporate purposes. Viracta Therapeutics is a clinical-stage drug development company advancing medicines based on a 'kick & kill' approach for viral-associated cancers. Its lead candidate, nanatinostat (VRx-3996), is being developed in combination with an antiviral as the first targeted, orally administered therapy for EBV-associated malignancies. Viracta is conducting a Phase 1b/2 clinical trial for EBV-associated lymphomas in the US and Brazil and plans to initiate a trial for EBV-associated solid tumors in the coming year. The company entered an exclusive collaboration and license agreement with Shenzhen Salubris to develop and commercialize the approach in China. Under the agreement Viracta received an equity investment and is eligible to receive up to $58 million in pre-commercial milestones, plus sales-level-triggered commercial milestones and tiered royalties. The partnership targets EBV-driven cancers that disproportionately affect patients in Southern China, including nasopharyngeal carcinoma, gastric carcinoma, and NK/T cell lymphomas. Viracta Therapeutics is a San Diego-based clinical-stage drug development company led by CEO Ivor Royston, M.D. The company advances medicines based on a proprietary viral gene activation therapeutic approach for viral-associated cancers and other serious diseases. Its lead candidate, VRx-3996, is a Class 1 histone deacetylase inhibitor (HDACi) in Phase 2 development for Epstein-Barr virus (EBV)-associated malignancies. Viracta will use the proceeds from the financing to advance VRx-3996 into Phase 2 clinical studies. The company agreed to an exclusive license of VRx-3996 to NantKwest for use in combination with NantKwest’s natural killer (NK) cell therapy platforms. NantKwest intends to transition VRx-3996 into human clinical trials combined with its aNK, haNK and taNK platforms. As part of the transaction, NantKwest Chairman and CEO Patrick Soon-Shiong will join Viracta’s Board as Vice Chairman.

Total raised

$143M

Funding rounds

5

Latest round

Debt Financing

Latest activity

Nov 2021